GlassScriptPhysician profile
Janet S Orr
NPI 1659367738
$301.10
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $112.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $57.39 | 2019-2020 | |
| Glaxosmithkline, LLC. | $50.87 | 2019 | |
| Tris Pharma INC | $28.38 | 2020 | |
| Cranial Technologies, INC | $27.00 | 2019-2020 | |
| Kaleo, INC. | $25.31 | 2019 | |
| Amneal Pharmaceuticals LLC | $19.17 | 2019 | |
| Genentech USA, INC. | $18.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.79 | 2020 | |
| Pfizer INC. | $17.15 | 2020 | |
| Sobi, INC | $15.84 | 2019 | |
| Merck Sharp & Dohme LLC | $12.16 | 2020 | |
| Shire North American Group INC | $11.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.